-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Biocryst Pharmaceuticals Inc quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2021 to Q2 2024.
- Biocryst Pharmaceuticals Inc Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $172K, a 76.8% decline year-over-year.
- Biocryst Pharmaceuticals Inc Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was -$564K, a 119% decline year-over-year.
- Biocryst Pharmaceuticals Inc annual Income Tax Expense (Benefit) for 2023 was $310K, a 88.7% decline from 2022.
- Biocryst Pharmaceuticals Inc annual Income Tax Expense (Benefit) for 2022 was $2.73M, a 21.3% increase from 2021.
- Biocryst Pharmaceuticals Inc annual Income Tax Expense (Benefit) for 2021 was $2.25M.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)